Literature DB >> 8229693

Binding of fluvastatin to blood cells and plasma proteins.

F L Tse1, D F Nickerson, W S Yardley.   

Abstract

The binding of fluvastatin, an inhibitor of hydroxymethylglutaryl coenzyme A reductase, to plasma proteins and red blood cells of rat, dog, and human in vitro was determined by ultrafiltration. Additionally, the stereospecificity of fluvastatin binding to proteins and the potential interaction between fluvastatin and the highly protein bound drugs warfarin, salicylic acid, and glyburide were investigated. Only a small fraction of fluvastatin in blood was taken up by the blood cells, amounting to 19-33% in the rat and < or = 15% in dog and humans. The plasma:blood fluvastatin ratio in these species at 37 degrees C was > or = 1.4. In human blood, this ratio was temperature independent. In the plasma concentration range 25-50,000 ng/mL, fluvastatin was > or = 98% bound to proteins. The binding was concentration dependent in the rat, but not in the dog and human. Both enantiomers of fluvastatin were > 99% bound in normal human plasma, the binding of each being unaffected by the presence of the other. A major fluvastatin-binding protein in human plasma was albumin, whereas binding to alpha 1-acid glycoprotein was relatively weak and concentration dependent. At therapeutic concentrations in normal human plasma, the protein binding of fluvastatin (0.1 microgram/mL) was unaffected by warfarin (1-10 micrograms/mL), salicylic acid (50-150 micrograms/mL), and glyburide (0.1-1 micrograms/mL). Similarly, fluvastatin had no influence on the binding of these compounds. In diluted human albumin solution (29 microM), bound fluvastatin was displaced by all three co-solutes tested.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8229693     DOI: 10.1002/jps.2600820914

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

Review 1.  Pediatric Statin Administration: Navigating a Frontier with Limited Data.

Authors:  Jonathan Wagner; Susan M Abdel-Rahman
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Sep-Oct

2.  Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects.

Authors:  Daisy Jindal; Monika Tandon; Sanjay Sharma; K K Pillai
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

Review 3.  Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.

Authors:  G L Plosker; A J Wagstaff
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 4.  Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Authors:  H Lennernäs; G Fager
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of fluvastatin.

Authors:  C D Scripture; J A Pieper
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 6.  Antihyperlipidaemic agents. Drug interactions of clinical significance.

Authors:  J A Farmer; A M Gotto
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 7.  Fluvastatin: clinical and safety profile.

Authors:  Alberto Corsini; Terry A Jacobson; Christie M Ballantyne
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Mechanistic approaches to volume of distribution predictions: understanding the processes.

Authors:  Trudy Rodgers; Malcolm Rowland
Journal:  Pharm Res       Date:  2007-03-20       Impact factor: 4.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.